Browse result page of THPdb

The total number entries retrieved from this search are 68

ID	ThPPID	Name	Peptide Sequence	Length	Functional Classification	Disease	Brand	Company	Physical Appearance	Route of Administartion	Category	Target
ID1649	ThPPIDTh1148	NameAliskiren	Peptide SequenceN.A. Full view	Length0	Functional ClassificationIIa	DiseaseMetabolic	BrandTekturna	CompanyNovartis Pharmaceuticals Corporation	Physical AppearanceLight-pink, biconvex round tablet	Route of AdministartionOral route	CategoryRenin inhibitor	TargetRenin
ID1650	ThPPIDTh1148	NameAliskiren	Peptide SequenceN.A. Full view	Length0	Functional ClassificationIIa	DiseaseMetabolic	BrandTekturna HCT	CompanyNovartis Pharmaceuticals Corporation	Physical AppearanceBiconvex, ovaloid film-coated tablets.	Route of AdministartionOral route	CategoryRenin inhibitor	TargetRenin
ID1651	ThPPIDTh1148	NameAliskiren	Peptide SequenceN.A. Full view	Length0	Functional ClassificationIIa	DiseaseMetabolic	BrandTekamlo	CompanyNovartis Pharmaceuticals Corporation	Physical AppearanceTablets (aliskiren/amlodipine): 150 mg/5 mg, 150 mg/10 mg, 300 mg/5 mg, 300 mg/10 mg	Route of AdministartionOral route	CategoryRenin inhibitor	TargetRenin
ID1652	ThPPIDTh1148	NameAliskiren	Peptide SequenceN.A. Full view	Length0	Functional ClassificationIIa	DiseaseMetabolic	BrandAmturnide	CompanyNovartis Pharmaceuticals Corporation	Physical AppearanceTablets (aliskiren/ amlodipine/ HCTZ): 150/5/12.5, 300/5/12.5, 300/5/25, 300/10/12.5, 300/10/25 mg.ÂÂÂ	Route of AdministartionOral route	CategoryRenin inhibitor	TargetRenin
ID1654	ThPPIDTh1150	NameSecukinumab	Peptide SequenceSecukinumab Heavy Ch Full view	Length672	Functional ClassificationIIa	DiseaseImmunological	BrandCosentyx	CompanyNovartis Pharmaceuticals Corporation	Physical AppearanceSterile, preservative-free, clear to slightly opalescent, colorless to slightly yellow solution.	Route of AdministartionSubcutaneous injection	CategoryInhibitor	TargetIL-17A cytokine
ID1661	ThPPIDTh1153	NameAlefacept	Peptide SequenceHeavy Chain: CFSQQIY Full view	Length705	Functional ClassificationIIa	DiseaseImmunological	BrandAmevive	CompanyAstellas Pharma Inc.	Physical AppearanceSterile, white-to-off-white, preservative-free, lyophilized powder	Route of AdministartionIntramuscular Injection	CategoryDermatologic and Immunosupressive agents	TargetT-cell surface antigen CD2, Complement C1r subcomponent, Complement C1q subcomponent subunit A, B, C, Low affinity immunoglobulin gamma Fc region receptor III-A,III-B, II-a, II-b, II-c
ID1667	ThPPIDTh1158	NameAprotinin	Peptide SequenceRPDFCLEPPYTGPCKARIIR Full view	Length58	Functional ClassificationIIa	DiseaseImmunological	BrandTrasylol	CompanyBayer Pharmaceuticals	Physical AppearanceClear, colorless, sterile isotonic solution	Route of AdministartionIntravenous administration	CategoryN.A.	TargetTrypsin-1, Chymotrypsinogen B, Plasminogen, Kallikrein-!
ID1703	ThPPIDTh1167	NameAtezolizumab	Peptide SequenceNA Full view	Length0	Functional ClassificationIIa	DiseaseCancer	BrandTecentriq	CompanyNA	Physical AppearanceNA	Route of AdministartionNA	CategoryNA	TargetNA
ID1741	ThPPIDTh1179	NameEvolocumab	Peptide SequenceNA Full view	Length0	Functional ClassificationIIa	DiseaseGenetic/Metabolic/Cardiac	BrandNA	CompanyNA	Physical AppearanceInjection, Solution; Injection	Route of AdministartionSubcutaneous	CategoryLipid Modifying Agents, Plain; Cardiovascular System	TargetProprotein convertase subtilisin/kexin type 9
ID1742	ThPPIDTh1179	NameEvolocumab	Peptide SequenceNA Full view	Length0	Functional ClassificationIIa	DiseaseGenetic/Metabolic/Cardiac	BrandRepatha	CompanyAmgen Inc	Physical AppearanceInjection, Solution	Route of AdministartionSubcutaneous	CategoryLipid Modifying Agents, Plain; Cardiovascular System	TargetProprotein convertase subtilisin/kexin type 10
ID1743	ThPPIDTh1179	NameEvolocumab	Peptide SequenceNA Full view	Length0	Functional ClassificationIIa	DiseaseGenetic/Metabolic/Cardiac	BrandRepatha	CompanyAmgen Canada Inc	Physical AppearanceSolution	Route of AdministartionSubcutaneous	CategoryLipid Modifying Agents, Plain; Cardiovascular System	TargetProprotein convertase subtilisin/kexin type 11
ID1744	ThPPIDTh1179	NameEvolocumab	Peptide SequenceNA Full view	Length0	Functional ClassificationIIa	DiseaseGenetic/Metabolic/Cardiac	BrandRepatha	CompanyAmgen Inc	Physical AppearanceInjection, Solution	Route of AdministartionSubcutaneous	CategoryLipid Modifying Agents, Plain; Cardiovascular System	TargetProprotein convertase subtilisin/kexin type 12
ID1797	ThPPIDTh1191	NameVedolizumab	Peptide SequenceHeavy Chain Sequence Full view	Length716	Functional ClassificationIIa	DiseaseImmunological Disorders	BrandEntyvio	CompanyTakeda Pharmaceuticals America, Inc.	Physical AppearanceInjection, Powder, Lyophilized, for Solution	Route of AdministartionIntravenous	CategoryImmunosupressive agent, Antineoplastic agent	TargetIntegrin alpha-4, Integrin beta-7
ID1802	ThPPIDTh1196	NameSiltuximab	Peptide SequenceHeavy Chain Sequence Full view	Length708	Functional ClassificationIIa	DiseaseImmunological Disorders	BrandSylvant	CompanyJanssen Inc	Physical AppearanceLyophilized Powder	Route of AdministartionIntravenous infusion	CategoryAntineoplastic and Immunomodulating Agents, Immunosuppressive Agents	TargetInterleukin-6
ID1826	ThPPIDTh1216	NameAnthrax immune globulin human	Peptide SequenceNA Full view	Length0	Functional ClassificationIIa	DiseaseImmunological Disorders	BrandANTHRASIL	CompanyCangene Corporation	Physical AppearanceLiquid	Route of AdministartionIntravenous	CategoryPlasma derivative	TargetProtective antigen
ID1830	ThPPIDTh1220	NameBrodalumab	Peptide SequenceNA Full view	Length0	Functional ClassificationIIa	DiseaseImmunological Disorders	BrandSiliq	CompanyNA	Physical Appearancesterile, preservative-free, clear to slightly opalescent, colorless to slightly yellow solution	Route of AdministartionSubcutaneous	CategoryAntineoplastic and Immunomodulating Agents	Target Interleukin 17 receptor A
ID1831	ThPPIDTh1221	NameC1 Esterase Inhibitor (Recombinant)	Peptide SequenceNA Full view	Length0	Functional ClassificationIIa	DiseaseCardiac Disorders	BrandRuconest	CompanyTjoapack Netherlands Bv	Physical AppearancePowder and liquid for solution	Route of AdministartionIntravenous	CategoryBlood and Blood Forming Organs	TargetComplement C1r subcomponent, Complement C1s subcomponent, Plasma kallikrein, Coagulation factor XII, Prothrombin, Coagulation factor XI, Tissue-type plasminogen activator
ID1832	ThPPIDTh1222	NameCanakinumab	Peptide SequenceH-GAMMA-1 Chain: QVQ Full view	Length842	Functional ClassificationIIa	DiseaseImmunological Disorders	BrandIlaris	CompanyNovartis	Physical AppearanceLyphilized powder	Route of AdministartionSubcutaneous	CategoryAntineoplastic and Immunomodulating Agents	TargetInterleukin-1 beta